GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Inovio Biomedical Corporation (INO) [hlAlert]

Rating:
Buy INO
up 168.46 %

Inovio Biomedical Corporation (INO) rated Buy with price target $14 by Maxim Group

Posted on: Tuesday,  Jan 5, 2016  4:25 PM ET by Maxim Group

Maxim Group rated Buy Inovio Biomedical Corporation (NASDAQ: INO) on 01/05/2016. Previously Maxim Group rated Buy Inovio Biomedical Corporation (NASDAQ: INO) on
01/31/2013., when the stock price was $2.60. Since then, Inovio Biomedical Corporation has gained 168.46% as of 01/05/2016's recent price of $6.98.
If you would have followed the previous Maxim Group's recommendation on INO, you would have gained 168.46% of your investment in 1069 days.

Inovio Biomedical Corporation (Inovio) is a San Diego-based biomedical company focused on the development of vaccines to prevent or treat cancers and chronic infectious diseases. Inovio develops deoxyribonucleic acid (DNA) delivery solutions based on electroporation, which uses brief, controlled electrical pulses to create temporary pores in cell membranes and enable increased cellular uptake of a useful biopharmaceutical. Once the DNA vaccine enters a cell, it can then express the proteins it was encoded to produce. Inovio has multiple systems designed to create different electroporation conditions for different applications consists of two documents: a pulse generator and an applicator that is inserted into selected tissue. The Company?s subsidiaries include Genetronics, Inc., Inovio AS and Inovio Asia Pte. Ltd. In June 2009, Inovio completed its merger with VGX Pharmaceuticals.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/5/2016 4:25 PM Buy
None
14.00
as of 8/27/2015
1 Week up  7.55 %
1 Month down  -23.21 %
3 Months down  -12.64 %
1 YTD down  -39.82 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/9/2015 8:25 AM Buy
None
7.24 23.00
3/18/2014 8:25 AM Buy
None
13.72 24.00
7/9/2013 1:25 PM Buy
None
4.72 8.00
1/31/2013 8:25 AM Buy
None
2.60 4.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy